Multiple Myeloma
Multiple Myeloma
Advertisement
Amy Pierre, RN, BSN, ANP-BCMultiple Myeloma | December 31, 2024
Amy Pierre, RN, BSN, ANP-BC, explains why it's important for advanced practice nurses to be invovled in research.
View More
Lisa Hwa, APRN, CNP, DNP, MSProfessional Development | December 27, 2024
Lisa Hwa, APRN, CNP, DNP, MS, is a member of the ASH Medical Educators Institute and has presented multiple ASH abstracts.
Beth Faiman, PhD, MSN, APN-BC, AOCN®, BMTCN®, FAAN, FAPOMultiple Myeloma | December 20, 2024
Beth Faiman, PhD, MSN, APN-BC, AOCN®, BMTCN®, FAAN, FAPO, shares her hopes for the new year.
Amy Pierre, RN, BSN, ANP-BCConferences | December 20, 2024
Amy Pierre, RN, BSN, ANP-BC, reflects on highlights from ASH 2024 and why it's critical for advanced practitioners to attend.
Samantha Shenoy, NPConferences | December 20, 2024
Samantha Shenoy, NP, shares why it's important for nurses and APPs to consider attending the annual meeting.
Beth Faiman, PhD, MSN, APN-BC, AOCN®, BMTCN®, FAAN, FAPOConferences | December 19, 2024
Beth Faiman, PhD, MSN, APN-BC, AOCN®, BMTCN®, FAAN, FAPO, discusses the significance of ASH 2024.
Amy Pierre, RN, BSN, ANP-BCConferences | December 18, 2024
Amy Pierre, RN, BSN, ANP-BC, shares insights and key action items from her ASH 2024 presentation on the topic.
Samantha Shenoy, NPConferences | December 11, 2024
Samantha Shenoy, NP, speaks about her experience at the meeting and key highlights in multiple myeloma research.
Beth Faiman, PhD, MSN, APN-BC, AOCN®, BMTCN®, FAAN, FAPOConferences | December 11, 2024
Beth Faiman, PhD, MSN, APN-BC, AOCN®, BMTCN®, FAAN, FAPO, explains key takeaways from her myeloma research at ASH 2024.
Elaine S. DeMeyer, RN, MSN, AOCN®, BMTCN®Multiple Myeloma | December 10, 2024
Learn how oncology nurses can assess for CRS and ICANS, which are the main side effects of CAR-T and BiTE therapies.
Elaine S. DeMeyer, RN, MSN, AOCN®, BMTCN®Multiple Myeloma | December 10, 2024
Oncology nurses must understand how these therapies are similar but different regarding therapy-specific side effects.
Cecilia BrownMultiple Myeloma | December 8, 2024
An analysis presented at ASH 2024 suggests the summation of evidence supports the therapy as a new standard of care.
Cecilia BrownConferences | November 18, 2024
The implementation of the process showed that outpatient administration is safe, well-tolerated, and reduced inpatient days.
Laura LitwinMultiple Myeloma | November 20, 2024
The post hoc study analysis showed that optimized bridging therapy is critical to disease control for multiple myeloma.
Laura LitwinMultiple Myeloma | November 17, 2024
Researchers studied DARA plus VRd as a new standard of care vs VRd alone in patients with newly-diagnosed multiple myeloma.
Laura LitwinMultiple Myeloma | November 15, 2024
The Patient Navigation Center at the Multiple Myeloma Research Foundation addresses barriers to care and supports patients.
Laura LitwinMultiple Myeloma | November 15, 2024
Talquetamab showed "robust and durable responses" for patients with relapsed/refractory multiple myeloma.
Elaine S. DeMeyer, RN, MSN, AOCN®, BMTCN®Multiple Myeloma | November 13, 2024
Oncology nurses may be the first to identify the classic triad of hyperviscosity syndrome symptoms.
Elaine S. DeMeyer, RN, MSN, AOCN®, BMTCN®Multiple Myeloma | November 8, 2024
Almost all patients with multiple myeloma at some point will develop bone disease—the “B” in CRAB.
Lisa Hwa, APRN, CNP, DNP, MSHematology & Blood Cancer | October 23, 2024
Lisa Hwa, APRN, CNP, DNP, MS, said the comprehensive fellowships will help prepare APPs working in complex specialties.
Advertisement
Advertisement
Advertisement